New hope for stubborn skin disease in small trial
NCT ID NCT06444399
Summary
This study is testing if an oral medication called Deucravacitinib is safe and effective for treating Pityriasis Rubra Pilaris (PRP), a rare and often severe inflammatory skin disease. It will enroll 12 adults with moderate-to-severe PRP to see if the drug improves their skin condition and quality of life over 24 weeks. The research also aims to find biological markers that might predict who will respond best to this treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PITYRIASIS RUBRA PILARIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Arizona
RECRUITINGScottsdale, Arizona, 85259, United States
Conditions
Explore the condition pages connected to this study.